Key result
Cancer history linked to ~2.6-fold higher 30-day mortality in patients with pulmonary embolism.
Why the study?
Many cancers and chemotherapies impair hemostatic physiology and increase thrombosis risk, prompting an evaluation of PE characteristics in cancer versus non-cancer patients.
Does a concurrent cancer diagnosis worsen prognosis and early mortality in patients with pulmonary embolism?
Observational (n=108)
No
Does a concurrent cancer diagnosis worsen prognosis and early mortality in patients with pulmonary embolism?
A concurrent cancer diagnosis in patients with pulmonary embolism significantly increases early mortality and disease severity without notably altering radiological or laboratory parameters.
Answers are grounded in this paper and cite their sources.
May warrant enhanced risk stratification for cancer patients with PE; leaves open whether targeted interventions reduce mortality.
Amaç: Genel olarak birçok kanserin ve kanseri önlemek için verilen kemoterapilerin hemostaz fizyolojisini bozarak tromboza eğilimi artırdığı bilinmektedir.Bu çalışmada kanser tanısı olan olgularda gelişen pulmoner emboli (PE) ile kanser tanısı olmayan PE olguları arasındaki prognostik farklılıklar araştırılmıştır.Gereç ve Yöntemler: Aralık 2021-Ocak 2023 tarihleri arasında kliniğimize PE tanısı ile yatan olguların dosyaları retrospektif olarak incelendi.Olgular öncesinde kanser tanısı olanlar ve olmayanlar olmak üzere 2 gruba ayrıldı.Her iki gruptaki olguların klinik, demografik, radyolojik ve laboratuvar özellikleri karşılaştırıldı.PE'nin prognostik değerlendirmesi için Pulmoner Emboli Şiddet İndeksi (PESİ) skoru kullanıldı, PE'nin şiddetinin sınıflandırılması ve erken mortalite değerlendirmesi (EMD) için olgular düşük, ortadüşük, orta-yüksek ve yüksek riskli olarak sınıflandırıldı.İki grubun verileri birbirleri ile karşılaştırıldı.Bulgular: Çalışmaya yaş ortalaması 65,5±18 olan toplam 108 olgu dahil edildi.Olguların 30'unda (%27,7) (Grup 1) öz geçmişinde kanser öyküsü var iken, 78'inin (%72,3) (Grup 2) öz geçmişinde kanser öyküsü yoktu.Grup 1'de olguların ortalama hastanede yatış gün ÖZBackground: In general, it is known that many cancers and chemotherapy regimens administered to prevent cancer increase the tendency for thrombosis by disrupting hemostasis physiology.In this study, the prognostic differences between pulmonary embolism (PE) in patients diagnosed with cancer and those without a cancer diagnosis were investigated. Materials and Methods:The records of patients diagnosed with PE in our clinic between December 2021 and January 2023 were retrospectively examined.Patients were divided into 2 groups: those with and without a history of cancer.Clinical, demographic, radiological, and laboratory characteristics of the patients in both groups were compared.Pulmonary Embolism Severity Index (PESI) score was used for the prognostic evaluation of PE.For the classification of the severity of PE and early mortality assessment (EMD) patients were stratified into low, moderate-low, moderate-high, and high-risk categories.The data of these two groups were compared.Results: A total of 108 patients, with a mean age of 65.5±18 years, were included in the study.Of these patients, 30 (27.7%) (Group 1) had a history of cancer, and 78 (72.3%) (Group 2) had no history of cancer.The mean duration of hospitalization was 7.3±5.4days in Group 1 and 9.7±5.2days in Group 2 (p<0.05).No significant difference was observed in D-dimer, brain natriuretic peptide, and troponin values (p>0.05).Thoracic computed tomography-angiography findings of both groups were also similar (p>0.05).In Group 1; mean PESI score and rate of the number of patients PESI-III and above were significantly higher (p<0.05).In terms of EMD, the rate of high-risk patients and incidence of hemodynamic instability were significantly higher in Group 1 (p<0.05).Concerning the 30 day mortality, the rate of number of patients in Group 1 was significantly higher (p<0.05). Conclusion:The presence of an additional cancer diagnosis did not have a notable impact on the radiological and laboratory parameters of PE; however, it did significantly change the early mortality associated with PE.
No takes yet. Share an insight, caveat, or question.
TAHTASAKAL et al. (2024) conducted an observational in Pulmonary embolism (n=108). History of cancer vs. No history of cancer was evaluated on 30-day mortality (p=0.047). A history of cancer in patients with pulmonary embolism was associated with a higher 30-day mortality rate compared to patients without cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: